A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy.

Authors:

Abstract
TPS5606 Background: Niraparib is a highly selective PARP1/2 inhibitor that induces synthetic lethality in tumor cells with homologous recombination DNA repair deficiencies (HRD). Niraparib is administered orally once daily (QD) and may be taken without regard to meals, because food does not significantly affect the absorption or metabolism of niraparib. In a phase 1 study, niraparib was clinically active and well tolerated in patients with ovarian cancer. To address the need for novel therapies for recurrence, a randomized, double-blind phase 3 study is evaluating niraparib as maintenance treatment in patients with stage III/IV HRD+ ovarian, fallopian tube, or primary peritoneal cancer who responded to front-line platinum-based chemotherapy but are at high risk for progressive disease, based on cancer stage, use of neoadjuvant therapy, and residual disease after primary surgery. Methods: This multicenter trial is enrolling ≈305 patients with ovarian, fallopian tube, or peritoneal cancer.Eligible females are required to have histologically diagnosed stage III/IV cancer, an HRD+ tumor (myChoice HRD test), normal or > 90% decrease in CA-125 levels during front-line therapy, and no prior PARP inhibitor use. Patients who have undergone debulking surgery must have residual disease after primary surgery unless they received neoadjuvant therapy. Patients with a known history of myelodysplastic syndrome (MDS) or a baseline cytogenetic test result with a risk for a diagnosis of MDS or acute myeloid leukemia are excluded. Patients must have completed ≥ 4 cycles of platinum-based therapy and had a complete or partial RECIST response. Patients are randomized (2:1) to receive niraparib 300 mg QD or matched placebo in 28-day cycles. Tumors are assessed every 12 weeks per RECIST v1.1. The primary endpoint is progression-free survival (PFS) by blinded central review. After 258 PFS events, the study will have 90% power (one-sided a = 0.025) to detect an improvement in median PFS with hazard ratio = 0.65. Secondary endpoints are evaluation of overall survival, patient-reported outcomes, safety and tolerability, and time to progression on next therapy. Clinical trial information: NCT02655016.